search
Back to results

Quebec Lung Cancer Screening PLUS Trial (QLC+)

Primary Purpose

COPD, Coronary Artery Calcification

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Educational material and treatment recommendations for patients, general practitioners and pharmacists
Sponsored by
Nicole Ezer, MD, FRCPC, MPH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for COPD focused on measuring COPD, Coronary Artery Calcification, Lung cancer screening, Undiagnosed disease, Educational intervention, Medication adherence, Untreated disease, Statins, Inhalers

Eligibility Criteria

55 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient screened for lung cancer as part of the Quebec Lung Cancer Demonstration project by low dose CT scan of the chest.
  • Cardiovascular aim: moderate to severe CAC identified on low dose CT, not on guideline recommended statin therapy.
  • COPD aim: diagnosed with COPD, symptomatic (mMRC 2 or greater) and untreated, or not on first line guideline recommended therapy for COPD. (ie. inhaled corticosteroids (ICS) alone or short acting beta agonists alone).

Exclusion Criteria:

  • Any participant with a high suspicion of lung cancer, defined as Lung-RADS (Lung Imaging Reporting and Data System) 3 or 4, as this is an inopportune time to initiate new medical therapies.
  • Cardiovascular aim: Absent or mild CAC, known clinical atherosclerosis, Diabetes Mellitus.
  • COPD aim: asymptomatic, or already on appropriate first line COPD therapy (LAMA, long acting beta agonist (LABA), combined LAMA-LABA, combined LAMA-LABA-ICS).

Sites / Locations

  • McGill University Health CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Other

No Intervention

Other

Arm Label

Control Arm: CVD

Intervention Arm: CVD

Control Arm: COPD

Intervention Arm: COPD

Arm Description

Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images

Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. CAC score obtained from lung cancer screening CT Scan images

Patients with untreated COPD or not on first line guideline recommended therapy.

Patients with untreated COPD or not on first line guideline recommended therapy.

Outcomes

Primary Outcome Measures

Guideline concordant statin therapy 1 year following the first low dose CT scan.
Among patients with moderate to severe coronary artery calcifications (CAC) not on a statin at baseline, any statin prescribed for primary prevention at least once in the 1 year following the first low dose CT scan. (aim 1)
Guideline concordant inhaler therapy 1 year following the first low dose CT scan
Among patients who have untreated or inappropriately treated COPD at baseline, any long acting muscarinic antagonist inhaler prescribed at least once in the 1 year following the first low dose CT scan (aim 2)

Secondary Outcome Measures

Medication possession ratio (MPR) - Aim 1
Reflects patient adherence. Days of drug supply over 1 year with cholesterol lowering medication in the previous 1 year from pharmacy dispensation records.
Medication possession ratio (MPR) - Aim 2
Reflects patient adherence. Days of drug supply over 1 year with guideline concordant inhaler therapy for COPD in the previous 1 year from pharmacy dispensation records.
COPD Symptoms
COPD Assessment Test is a validated patient-reported outcome. It measures 8 symptoms of COPD on a 0-5 point scale at baseline, 6 and 12 months post intervention
Quality of life using SF-36 questionnaire
SF-36 questionnaire will be filled at baseline and 12 months post intervention
Patient satisfaction with communication and decision making
COMRADE is a 20-item self-reported measure for use in primary care to assess risk communication and confidence in treatment decision making. It assesses patient satisfaction with information provided about risks/benefits of treatment, perception of participation in treatment decisions, and satisfaction with that decision. COMRADE questionnaire will be sent to patients after their first meeting with their general practitioner up to 3 months after intervention.
Health Care Utilisation
Number of unplanned clinic visits, hospitalizations for respiratory or cardiac disease, consultations with specialists (cardiology and respirology), invasive/non-invasive cardiac or respiratory investigations
Absenteeism and presenteeism
Work productivity and activity impairment (WPAI) questionnaire
Health literacy
Health literacy will be assessed at study entry using the Brief Health Literacy Screen.

Full Information

First Posted
June 27, 2022
Last Updated
July 20, 2023
Sponsor
Nicole Ezer, MD, FRCPC, MPH
search

1. Study Identification

Unique Protocol Identification Number
NCT05444062
Brief Title
Quebec Lung Cancer Screening PLUS Trial
Acronym
QLC+
Official Title
Quebec Lung Cancer Screening PLUS Trial - a Randomized Controlled Trial of an Educational Intervention for Untreated Chronic Obstructive Pulmonary Disease (COPD) and/or Cardiovascular Disease (CVD) Identified During Lung Cancer Screening
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 23, 2023 (Actual)
Primary Completion Date
September 2026 (Anticipated)
Study Completion Date
September 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Nicole Ezer, MD, FRCPC, MPH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD, Coronary Artery Calcification
Keywords
COPD, Coronary Artery Calcification, Lung cancer screening, Undiagnosed disease, Educational intervention, Medication adherence, Untreated disease, Statins, Inhalers

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
330 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control Arm: CVD
Arm Type
No Intervention
Arm Description
Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images
Arm Title
Intervention Arm: CVD
Arm Type
Other
Arm Description
Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. CAC score obtained from lung cancer screening CT Scan images
Arm Title
Control Arm: COPD
Arm Type
No Intervention
Arm Description
Patients with untreated COPD or not on first line guideline recommended therapy.
Arm Title
Intervention Arm: COPD
Arm Type
Other
Arm Description
Patients with untreated COPD or not on first line guideline recommended therapy.
Intervention Type
Behavioral
Intervention Name(s)
Educational material and treatment recommendations for patients, general practitioners and pharmacists
Intervention Description
Educational material and treatment recommendations given to patients, their family doctors and their pharmacists.
Primary Outcome Measure Information:
Title
Guideline concordant statin therapy 1 year following the first low dose CT scan.
Description
Among patients with moderate to severe coronary artery calcifications (CAC) not on a statin at baseline, any statin prescribed for primary prevention at least once in the 1 year following the first low dose CT scan. (aim 1)
Time Frame
1 year post CT
Title
Guideline concordant inhaler therapy 1 year following the first low dose CT scan
Description
Among patients who have untreated or inappropriately treated COPD at baseline, any long acting muscarinic antagonist inhaler prescribed at least once in the 1 year following the first low dose CT scan (aim 2)
Time Frame
1 year post CT
Secondary Outcome Measure Information:
Title
Medication possession ratio (MPR) - Aim 1
Description
Reflects patient adherence. Days of drug supply over 1 year with cholesterol lowering medication in the previous 1 year from pharmacy dispensation records.
Time Frame
1 year post CT
Title
Medication possession ratio (MPR) - Aim 2
Description
Reflects patient adherence. Days of drug supply over 1 year with guideline concordant inhaler therapy for COPD in the previous 1 year from pharmacy dispensation records.
Time Frame
1 year post CT
Title
COPD Symptoms
Description
COPD Assessment Test is a validated patient-reported outcome. It measures 8 symptoms of COPD on a 0-5 point scale at baseline, 6 and 12 months post intervention
Time Frame
Baseline, 6 months post intervention, 12 months post intervention
Title
Quality of life using SF-36 questionnaire
Description
SF-36 questionnaire will be filled at baseline and 12 months post intervention
Time Frame
Baseline, 12 months post intervention
Title
Patient satisfaction with communication and decision making
Description
COMRADE is a 20-item self-reported measure for use in primary care to assess risk communication and confidence in treatment decision making. It assesses patient satisfaction with information provided about risks/benefits of treatment, perception of participation in treatment decisions, and satisfaction with that decision. COMRADE questionnaire will be sent to patients after their first meeting with their general practitioner up to 3 months after intervention.
Time Frame
3 months post intervention
Title
Health Care Utilisation
Description
Number of unplanned clinic visits, hospitalizations for respiratory or cardiac disease, consultations with specialists (cardiology and respirology), invasive/non-invasive cardiac or respiratory investigations
Time Frame
1 year post intervention
Title
Absenteeism and presenteeism
Description
Work productivity and activity impairment (WPAI) questionnaire
Time Frame
baseline
Title
Health literacy
Description
Health literacy will be assessed at study entry using the Brief Health Literacy Screen.
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient screened for lung cancer as part of the Quebec Lung Cancer Demonstration project by low dose CT scan of the chest. Cardiovascular aim: mild to severe CAC identified on low dose CT, not on guideline recommended lipid-lowering therapy. COPD aim: diagnosed with COPD, symptomatic (mMRC >=1 or CAT>= 10) and untreated, or not on first line guideline recommended therapy for COPD. Exclusion Criteria: Any participant with a high suspicion of lung cancer, defined as Lung-RADS (Lung Imaging Reporting and Data System) 3 or 4, as this is an inopportune time to initiate new medical therapies. Cardiovascular aim: Absent CAC, known clinical atherosclerosis, known former heart surgery, Diabetes Mellitus. COPD aim: asymptomatic, or already on appropriate first line COPD therapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicole Ezer, MD
Phone
(514)-934-1934
Ext
76192
Email
nicole.ezer@mcgill.ca
Facility Information:
Facility Name
McGill University Health Center
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3K 2M2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Ezer, MD MPH
Phone
5149341934
Ext
76192
Email
nicole.ezer@mcgill.ca
First Name & Middle Initial & Last Name & Degree
Charlotte Besson, PHD
Phone
4508484141
Email
charlotte.besson@muhc.mcgill.ca
First Name & Middle Initial & Last Name & Degree
Emily McDonald, MD MSc

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Quebec Lung Cancer Screening PLUS Trial

We'll reach out to this number within 24 hrs